anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pain caused by lumbar disc herniation (LDH) severely compromises patients' quality of life. The combination of steroid and local anesthetics is routinely employed in clinics to alleviate LDH-induced pain. However, the approach only mediates transient efficacy and requires repeated and invasive lumbar epidural injections. Here a paravertebrally-injected multifunctional hydrogel that can efficiently co-load and controlled release glucocorticoid betamethasone and anesthetics ropivacaine for sustained anti-inflammation, reactive oxygen species (ROS)-removal and pain relief in LDH is presented. Betamethasone is conjugated to hyaluronic acid (HA) via ROS-responsive crosslinker to form amphiphilic polymer that self-assemble into particles with ropivacaine loaded into the core. Solution of drug-loaded particles and thermo-sensitive polymer rapidly forms therapeutic hydrogel in situ upon injection next to the herniated disc, thus avoiding invasive epidural injection. In a rat model of LDH, multifunctional hydrogel maintains the local drug concentration 72 times longer than free drugs and more effectively inhibits the expression of pro-inflammatory cytokines and pain-related molecules including cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2). Therapeutic hydrogel suppresses the LDH-induced pain in rats for 12 days while the equivalent dose of free drugs is only effective for 3 days. This platform is also applicable to ameliorate pain caused by other spine-related diseases.
Study Design: This is an open-label, dose exploration study evaluating AMG 232 in subjects with advanced p53WT solid tumors or multiple myeloma. The study will be conducted in 2 parts: Part 1 - Dose Exploration (parts 1a, 1b and 1c) and Part 2 - Dose Expansion. Part 1a is aimed at evaluating the safety, tolerability, PK and PD of AMG 232 and determining the MTD of a 7-day once daily (QD) dosing schedule in subjects with advanced solid tumors using a practical continuous reassessment method (CRM). Part 1b will evaluate the safety and tolerability of 3-day QD dosing schedule (or alternate dosing schedule based upon emerging data) with a particular emphasis on evaluating the tolerability of daily doses equal to or higher than the part 1a MTD in subjects with solid tumors or multiple myeloma. Part 1c will evaluate the safety and tolerability of 7-day twice daily (BID) dosing schedule with daily cumulative doses equal to or higher than the part 1a MTD in subjects with solid tumors. The dose expansion part of the study (Part 2) can open once the MTD has been determined in Part 1a. Part 2, part 1b and part 1c can be explored in parallel. The dose expansion part will consist of up to 85 additional subjects with specific tumors harboring MDM2 amplification (liposarcoma \[LPS\], gliobastoma \[ GBM \] and all other solid tumors) or potentially harboring MDM2 overexpression (ER+ metastatic breast cancer) and a group of subjects with multiple myeloma.
After lung transplantation the production of de novo DSA directed against HLA-DQ molecules is associated with CLAD and graft loss. The most used assay for serum DSA detection is the Single Antigen Luminex® (SAG), which provides a semi-quantitative fluorescence value, the MFI, used as a surrogate of DSA "strength". But MFI is not perfectly associated with CLAD development. We developed a method using SPR allowing the concentration, kinetics (ka, kd) and affinity parameters (KD) of anti-DQ DSA to be determined. These quantitative parameters could represent biomarkers finely associated with CLAD. The way this parameters evolve (stability, increase or decrease) with time could also impact on DSA pathogenicity. We will compare the quantitative parameters of de novo anti-HLA DQ DSA, determined at the time of their discovery, between recipients that developed a CLAD for the 2 years following DSA apparition, and those who did not. The association between quantitative parameters of DSA and graft loss, their evolution and its association with CLAD and graft loss, and their correlation with SAG MFI will be also evaluated.
OBJECTIVE: Pragmatic trials often implement an intervention across a population of patients but require information unavailable at the population level that must be reported by a subset of patients. In this pragmatic clinical trial, we compared characteristics of seriously ill patients with those who completed a survey evaluating advance care planning across 3 academic health systems.
METHODS: A deliberate process including health system and external stakeholders and patients was used to design materials for and the approach to seriously ill patients. We developed a survey and conducted a multistep process to identify seriously ill primary care patients. We evaluated the relationships of age, gender, race and ethnicity, and vulnerability using the social vulnerability index in this population, and explored the representativeness of survey respondents compared with the underlying seriously ill population in terms of age, race and ethnicity, and vulnerability measured.
RESULTS: About 5% (8707 patients) of the primary care population was classified as seriously ill, 5351 were mailed a survey and 1100 provided survey responses. Hispanic and Black patients were younger than White patients, and Black and Hispanic patients were more vulnerable than White and Asian patients and patients of other races. Representativeness was high across age and race and ethnicity, although White and Hispanic patients were more likely to respond than Black and Asian patients and patients of other races. Vulnerability in the surveyed sample was nearly identical to the population.
CONCLUSIONS: A tailored survey and recruitment strategy yielded a representative sample of seriously ill, largely older, primary care respondents in the context of a pragmatic clinical trial.
The invention relates to the pharmaceutical industry, Para-pharmaceutical product industry and food industry, and issues affecting the development of compositions that are natural source of vitamins, trace elements and fibers. Purpose of the invention is to develop biologically active compositions for the form of tablets that are composed of cranberries and red bilberries preserved native (unaltered) form. In addition, in cranberry and lingonberry berries existing valuable substances can maintain over a long period, incorporating them in tablet form. Thus making it more convenient use, easy to use, easy packaged, transported and relatively cheap (economical), as well as access through the year, i.e., much longer period in comparison with fresh berries. The target reaches based on the fact that the composition contains cranberry and lingonberry marc powders that are components of peel, pulp and seeds, and excipients in certain relationships (mass %). Composition is obtained by drying cranberry and lingonberry berries at the temperature up to 40 oC. After drying the bled consists of granules, pellets then set up the press in tablets.
The application relates to the technical field of alopecia prevention, and particularly discloses an essential oil composition for scalp care and a preparation method thereof, which can improve alopecia caused by scalp grease secretion disorder and the like. The essential oil composition for scalp care comprises a main agent and a solvent, wherein the main agent comprises beta-ethyl ketobutyrate, catechin, cyanidin-3-O-glucoside, alpha-pinene, O-hydroxyacetone, nitric acid-phylline, tretinoin, 3-amino-2,6-piperidione and ergosterol. The combination of the beta-ethyl ketobutyrate, cyanidin-3-O-glucoside and the beta-ethyl ketobutyrate can reduce the effect of androgen secreted by women on hair follicles and reduce the probability of alopecia. Alpha-pinene and catechin can enhance the effect of killing germs. The o-hydroxyacetone can permeate pores to clean impurities. The nitric acid-phylline can accelerate the shedding of necrotic epidermal cells and improve the cleaning effect. The combination of tretinoin, 3-amino-2,6-piperidione and ergosterol can promote hair growth, regulate lipid balance, and treat scalp inflammation.
As with all AEDs, VIGADRONE should be withdrawn gradually. However, if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered. Patients and caregivers should be told not to suddenly discontinue VIGADRONE therapy.

In controlled clinical studies in adults with complex partial seizures, vigabatrin was tapered by decreasing the daily dose 1000 mg/day on a weekly basis until discontinued.

In a controlled study in pediatric patients with complex partial seizures, vigabatrin was tapered by decreasing the daily dose by one third every week for three weeks.

In a controlled clinical study in patients with infantile spasms, vigabatrin was tapered by decreasing the daily dose at a rate of 25 to 50 mg/kg every 3 to 4 days .
Coccygodynia often develops from an inappropriate sitting position or when standing up from a sitting position. In the advanced stages of coccydynia, the pain becomes continuous. Conservative treatment, interventional procedures and surgical treatment are used in treatment. Medical treatment, physical therapy and local injection applications are accepted as conservative treatment methods.Among the physical therapy modalities, ultrasound has been used for many years in diseases affecting the musculoskeletal system. Ultrasound, which is used for diagnostic and therapeutic purposes, can be applied in two ways as continuous and intermittent for therapeutic purposes.

A total of 52 patients who applied between 01/04/2021 and 01/04/2022 and met the inclusion and exclusion criteria will be included in the study. Continuous ultrasound will be performed in 26 patients and intermittent ultrasound will be performed in 26 patients. Randomization will be determined by the treatment protocol prepared in closed envelopes.Within the scope of the study, the age, height, weight, trauma history, duration of complaint, severity of pain and Oswestry Disability Index scale will be recorded before the interventions. The patients will be followed up at the 3rd week and 3rd month after the treatment. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS).

Data will be entered into SPSS (version: 22.0) IBM SPSS statistical package program. Arithmetic mean, standard deviation, min-max, median values will be given in the data obtained by measurement. Percentage and frequency distribution will be given in the data obtained by counting. In statistical evaluations, parametric tests will be used for data showing normal distribution, and non-parametric tests will be used for data not showing normal distribution. Relationships will be compared according to the Pearson or Spearman correlation coefficient. Chi-square test will be applied to categorical data. P\<0.05 will be considered significant.
To achieve these goals, the investigators will perform pilot MRI studies with kidney transplant patients. The investigators will study if MRI can reflect different levels of kidney function. The investigators will also evaluate if MRI can differentiate causes for declining kidney function. Finally, the investigators will explore how MRI measures changes before and after medical treatment for worsening kidney function.

Subjects may be invited for MRI exams with different exam options. An MRI exam may use either of two types of MRI machines at the CMRR: the 3T scanner and the 7T scanner. Subjects may also be invited for a multi-session exam. A description of the MRI exam types with different exam options and the types of multi-session exams is provided later in this document.
The present invention provides methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of ATF5. The present invention also provides methods for promoting or suppressing differentiation of stem/progenitor cells, for producing differentiated cells and for isolating/purifying differentiated cells, including neural cells. Also provided are differentiated cells, cell populations and transgenic animals comprising same and uses of same. The present invention further provides methods for treating nervous tissue degeneration and for identifying an agent for use in treating nervous tissue degeneration. Methods for promoting apoptosis in neoplastic cells and for treating or preventing tumors, and identifying agents for use in treating or preventing tumors are also provided by the present invention. The present invention further provides methods for identifying agents that inhibit ATF5, agents identified by these methods. Also provided are methods for diagnosing tumors, for assessing the efficacy of therapy to treat tumors and for assessing the prognosis of a subject who has a neural tumor. Finally, the present invention provides a kits for use in detecting and treating tumors.
Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19/22CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19/22CAR T-cells.
The invention relates to a cationic graft copolymer and a preparation method and application thereof. The copolymer is formed by that polyethyleneimine is covalently linked with oxidized 2 and 3 positions in a hyaluronic acid disaccharide unit. The preparation method is as below: the hyaluronic acid is dissolved in appropriate solvent, an oxidant is added in to be stirred and react, a stopping agent is added in to stop the reaction, and then the reaction solution is dialyzed in appropriate dialysate and dried, finally oxidative hyaluronic acid is obtained; the polyethyleneimine and the oxidative hyaluronic acid are dissolved in appropriate solvent to be stirred and react for a while; after the reaction, the solution is treated by reducing agent; and then the reaction solution is dialyzed in appropriate dialysate and dried, finally the cationic graft copolymer is obtained. The cationic graft copolymer is applicable in the filed of gene vectors. The invention also involves complex consisting of copolymer and plasmid DNA, and preparation methods and application thereof. Copolymer has targeting ability and hydrophilicity as well as wide gene adaptability, so the complex consisting of the copolymer and the plasmid DNA has very good targeting ability, safety and quite high transfection efficiency.
The invention discloses application of GW3965 (3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2, 2)-biphenylethyl)amino]propoxy)phenylacetate hydrochloride) in preparation of drugs treating or preventing hepatitis C virus. A drug without any toxic concentration is chosen for an antiviral experiment, the influence of GW3965 on virus gene duplication is detected, and results show that the small molecule compound has significant antiviral activity and is dose dependent. Then, the GW3965 is employed to treat the hepatitis C pseudovirus system of different gene subtypes, and results show that the compound inhibits the virus entrance link at the early stage of a virus lifecycle. The anti-virus capability of drug combination of GW3965 and other anti-HCV drugs is detected, and results show that the compound has the potential of drug combination with other drugs. GW3965 can inhibit 1a, 1b, and 2a genotype virus entrance, and has broad-spectrum antiviral activity and a novel target, while there is no anti-hepatitis C virus drug with entrance as the target clinically. And drug combination can achieve a good effect.
Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
Young patients (\< 65 year old) who contracted VIDOC 19 and were hospitalized for less than 7 days during the first wave, and who present cognitive disorders may be definitively included in the Neurocog-Covid study if their neuropsychological assessment is abnormal. They will then have a prescription for a cerebral MRI and will be enrolled in the TEP-Covid study. If they accept, they will receive a 18F-FDG PET-CT .
Shame is an emotion that can have significant negative impacts on health outcomes, including engagement in care. Feelings of shame are commonly experienced with stigmatized behaviors, such as substance misuse, and may be particularly strong among pregnant women who misuse substances. Rates of opioid misuse during pregnancy are dramatically rising, particularly in New Mexico, leading to negative health outcomes for mothers and fetuses. Shame has been found to decrease these patients' willingness to attend and engage in care. Although a theoretical model is available to guide interventions to reduce shame, it has not been tested empirically. In the current study, investigators seek to evaluate the preliminary effectiveness and feasibility of a brief Shame Resilience Intervention among women seeking care in UNM's Milagro program, a prenatal medical clinic for opioid using pregnant women. This research has the potential to significantly improve public health by generating a tool to reduce barriers to care.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. 

In clinical studies with bimatoprost ophthalmic solutions (0.01% or 0.03%) the most common adverse event was conjunctival hyperemia (range 25% – 45%). Approximately 0.5% to 3% of patients discontinued therapy due to conjunctival hyperemia with 0.01% or 0.03% bimatoprost ophthalmic solutions. Other common events (>10%) included growth of eyelashes, and ocular pruritus. 

Additional ocular adverse events (reported in 1 to 10% of patients) with bimatoprost ophthalmic solutions included ocular dryness, visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, eyelash darkening, eye discharge, tearing, photophobia, allergic conjunctivitis, asthenopia, increases in iris pigmentation, conjunctival edema, conjunctival hemorrhage, and abnormal hair growth. Intraocular inflammation, reported as iritis was reported in less than 1% of patients. 

Systemic adverse events reported in approximately 10% of patients with bimatoprost ophthalmic solutions were infections (primarily colds and upper respiratory tract infections). Other systemic adverse events (reported in 1 to 5% of patients) included headaches, abnormal liver function tests, and asthenia.
A system and method for controlling quality of performance of a digital application is disclosed. Performance data representing test results of a requested performance test on the application is obtained. A performance metric is optimized by analyzing the performance data and classifying analysis results of the analyzing into multiple categories, including an immediate remediation category. An automated modification is initiated based on a first analysis result classified into the immediate remediation category. An automated verification performance test determines a measure of improvement in performance of the application based on the modification by comparing a first verification result of a first performance test without the automated modification with a second verification result of a second performance test of the digital application with the automated front end modification. The digital application with the automated modification may be deployed based on a result of the automated verification performance test.
PURPOSE:To obtain the titled inhibitor containing a Bowman-Birk type trypsin inhibitor derived from soybean as an active ingredient. CONSTITUTION:A degranulation inhibitor for mast cells obtained by containing a Bowman-Birk type trypsin inhibitor derived from soybean (BBI; 6,000-8,000 mol.wt., present in water-soluble fraction of soybean together with a Kunitz type trypsin inhibitor having about 20,000mol.wt.) as an active ingredient. The natural BBI is obtained by concentration and fractionation using extraction with an aqueous medium or polar organic solvent, e.g. lower alcohol, lower aliphatic ketone, etc., separation with a membrane, isoelectic precipitation, etc., to give a crude purified substance, subjecting the resultant substance to purifying means, e.g. gel filtration, etc. Since the BBI is capable of acting on mast cells and inhibiting the degranulation thereof, it may be effective against allergic diseases.
The purpose of this study is to investigate the interaction between glycine and D-cycloserine in alcoholic patients and healthy subjects. Preclinical studies have shown that compounds acting at the glycine site of the N-methyl-D-aspartate (NMDA) receptor complex, such as glycine, may reverse the effects of ethanol on the NMDA receptor function (Rabe et al., 1990). The amino acid glycine is a co-agonist of the NMDA receptor complex (Kemp et al., 1993). It binds to the strychnine-insensitive site and positively modulates the NMDA receptor (Mc Donald et al., 1990). Physiologically, the glycine site is not saturated, and administration of glycine can potentiate NMDA receptor mediated responses. In contrast, D-cycloserine (Hood et al., 1989) is a partial-agonist at the glycine site of the NMDA receptor, with dose-dependent NMDA antagonist properties. The NMDA antagonist activity of D-cycloserine should produce ethanol like-effects that can be reversed by the agonist glycine. This study is intended to evaluate possible contributions of the glycine site to the reduction of cognitive deficits of alcoholism and complements the current work at VA Connecticut Healthcare System on the NMDA antagonists in alcoholic and healthy subjects.
NEW MATERIAL:The condensed heterocyclic compound of formula I (R1-R3 are H or lower alkyl; R4 and R5 are H, lower alkyl or together with adjacent N- atom form an aliphatic cyclic amino group; n is 1 or 2; m is 0 or 1). EXAMPLE:1, 3, 4, 6-Tetrahydro-6-methyl-8-morpholinomethyl-2H-5, 1-benzothiazocine. USE:It suppresses the secretion of gastric juice, and is useful as an antiulcer agent. It can be administered orally or parenterally by injection. PREPARATION:The compound of formula I can be produced by reacting the omega- substituted-thioalkylaniline derivative of formula II with a halogen or an active halogen compound, subjecting the resultant novel compound of formula III (Y is halogen) to ring-condensation reaction, and if necessary, alkylating the product or alkylating, acylating and e.g. reducing the product.